CLINICAL STUDY

Acute estrogen exposure does not affect basal very low-density lipoprotein–triglyceride production or oxidation in postmenopausal women

Lars C Gormsen1,2, Christian Høst1, Britta Eilersen Hjerrild1, Claus H Gravholt1 and Søren Nielsen1

1Medical Department M (Endocrinology and Diabetes), Aarhus University Hospital, DK-8000 Aarhus, Denmark and 2Department of Nuclear Medicine, Aarhus University Hospital, Skejby, DK-8200 Aarhus N, Denmark

(Correspondence should be addressed to L C Gormsen; Email: lars.christian.gormsen@ki.au.dk)

Abstract

Context: Long-term hormone replacement therapy (HRT) with estradiol (E2) is associated with an altered lipid profile including unfavorable increases in triglyceride (TG) concentrations and augmented hepatic very low-density lipoprotein (VLDL)–TG production. There are indications that this effect of estrogens may be immediate.

Objective: To study the in vivo effect of a single dose of E2 on VLDL–TG kinetics and oxidation in humans.

Methods: Eight healthy, postmenopausal women were given a single dose of either placebo or E2 (4 mg) orally. VLDL–TG kinetics was assessed by a 240-min primed-continuous infusion of ex vivo labeled [1-14C]triolein-labeled VLDL. Fractional and absolute VLDL–TG oxidation was determined by hyamin trapping of exhaled 14C label. Indirect calorimetry provided measurements of lipid oxidation.

Results: Administration of 4 mg of E2 orally rapidly increased plasma E2 concentrations from below detection threshold to premenopausal levels. Free fatty acids (FFA) and TG concentrations were unaltered. No immediate effect was observed on either VLDL–TG production (placebo versus E2): 20.0 ± 12.4 vs 24.1 ± 10.7 μmol/min, P = 0.33; VLDL–TG oxidation: 12.3 ± 10.9 vs 12.6 ± 5.6 μmol/min, P = 0.93); or VLDL–TG clearance rates: 51.4 ± 16.8 vs 64.9 ± 28.8 ml/min, P = 0.34).

Conclusions: Short-term E2 elevation does not affect VLDL–TG production, oxidation, or clearance in humans. We therefore propose that HRT-associated dyslipidemia has a gradual rather than immediate onset.

Introduction

Postmenopausal hormone replacement therapy (HRT) is associated with favorable changes in lipid profile including lowered levels of low-density lipoprotein (LDL) and increased high-density lipoprotein (HDL) (1). Administration of estrogens, however, may cause hypertriglyceridemia, a non-favorable effect (2) on the individual’s risk of developing cardiovascular disease. Increased concentrations of circulating triglycerides (TGs) may stem from either: i) increased hepatic production and secretion of TG rich very low-density lipoproteins (VLDLs), or ii) reduced peripheral clearance by lipoprotein lipase (LPL), hepatic lipase, direct catabolism, and/or LPL receptors (3). Whereas LPL activity is modified by estradiol (E2) according to whether the enzyme is located in muscle or adipose tissue, there is now general agreement that long-term estrogen administration augments hepatic VLDL production (1) and leads to elevated TG levels.

Although it is certainly possible that the TG increasing effect of estrogens may develop gradually over weeks and months, there are indications that the effect may be more immediate. Animal studies indicate that the hypertriglyceridemic effect of estrogen may have an acute onset. Thus, cultured chick hepatocytes stimulated by estrogen for 3 h secrete significantly more VLDL particles than control hepatocytes (4). Moreover, both APOB mRNA and secretion of VLDL increase following a single injection of either diethylstilbestrol (5) or E2 (6), an effect possibly mediated by the activation of membrane-bound estrogen receptors (ERs), enabling rapid cellular signaling (7). Thus, the effect of E2 on lipid metabolism and hence on body composition appears to be direct and mediated via ERs. These observations have led to renewed interest in adipocyte receptor subgroups, and recently, Dos Santos et al. (8) demonstrated the existence of a membrane-bound ERz. In that study, the authors demonstrated that physiological concentrations of E2 rapidly lead to activated p42/p44
MAPK, and that this effect could be blocked by an estrogen antagonist. Furthermore, infusion of conjugated estrogens increases insulin action within hours, and decreases plasma glycerol concentrations during a hyperinsulimemic euglycemic clamp (9), rendering it plausible that a range of signaling cascades is activated acutely by E2.

No previous study has assessed whether E2 has an immediate effect on hepatic VLDL–TG production in humans; thus, we studied the effect of oral administration of 4 mg E2 on VLDL–TG kinetics and oxidation in postmenopausal women using ex vivo labeled [1-14C]triolein and the primed-constant isotope dilution technique (10).

Materials and methods

Subjects

The participants were eight healthy, postmenopausal women (56 ± 4 years, 65 ± 8 kg body weight, 24.2 ± 1.2 kg/m² body mass index, 40 ± 4 kg lean body mass (LBM), 22 ± 5 kg fat mass). None used HRT, and all had E2 levels below 0.07 nM. Informed consent as well as ethics committee approval was obtained from all participants prior to the study, which was conducted in accordance with the Declaration of Helsinki II. Volunteers were recruited from an ongoing study of LBM, 22 kg fat mass). None used HRT, and all had E2 levels below 0.07 nM. Informed consent as well as ethics committee approval was obtained from all participants prior to the study, which was conducted in accordance with the Declaration of Helsinki II. Volunteers were recruited from an ongoing study of

Protocol

The subjects were examined on 2 days separated by 1 month. On all examination days, the subjects received either placebo or E2 (4 mg) at 0600 h (t = −120 min) after a 10-h overnight fast. Two i.v. catheters were inserted – one in an antecubital vein for infusion of the VLDL tracer and saline, and the other one in a dorsal vein on the contralateral hand. The latter was used for blood sampling. The hand was placed in a heated box in order to obtain arterialized blood. At t = 0 min, a bolus followed by a constant infusion of VLDL tracer was administered. The VLDL infusion was maintained for 240 min, and blood samples for determination of VLDL–TG concentration, specific activity (SA), and metabolites were drawn at t = 0 min, 180, 210, and 240 min. Indirect calorimetry was performed for 30 min from t = 210 min.

VLDL tracer preparation

The procedure used to label the TG moiety of the VLDL particle ex vivo has been described previously in detail (11). In brief, 80-ml blood was drawn from each participant, plasma was separated by a short spin, 30 μCi [1-14C]triolein (PerkinElmer, Inc., Turku, Finland) dissolved in 300 μl ethanol (Merck & Co., Inc.) was added, and the solution was then sonicated at 37 °C for 6 h. Subsequently, labeled VLDL particles were separated from other particles in plasma by 18 h of ultracentrifugation at 98 350 g and 4 °C. Samples were tested for bacterial growth to ensure sterility, and the solutions were stored at 4 °C until use (<1 week).

VLDL–TG concentration and SA

VLDL particles were isolated from ~3 ml of each plasma sample by ultracentrifugation as described above. The supernatant containing the VLDL fraction was obtained by tube slicing (Beckman Instruments, Inc., Palo Alto, CA, USA). Then, 300 μl were transferred to a scintillation vial, and 14C activity was measured by dual-channel liquid scintillation counting to <2% counting error (11).

Breath 14CO2-SA

Subjects expired into breath bags (IRIS-breath-bags; Wagner Analysen Technik, Bremen, Germany), and exhaled air passed through a solution containing benzethonium hydroxide (Sigma–Aldrich, Inc.) with thymolphthalein (Sigma–Aldrich, Inc.) in a scintillation vial. A color change (blue to clear) occurred when exactly 0.25 mmol CO2 was trapped in the solution. Scintillation fluid was added to the vial, and 14CO2 activity was measured by liquid scintillation counting to <2% counting error.

Indirect calorimetry

CO2 flow and substrate oxidation rates (12) were measured by indirect calorimetry (Deltatrac monitor, Datex Instrumentarium, Helsinki, Finland). After 5 min, adaptation to the hood VCO2 measurements was averaged from t = 185 to 210 min.

Calculations

VLDL–TG production – primed-constant infusion:

VLDL production and clearance rates were calculated as described in detail previously (10):

\[
\text{VLDL–TG Ra (μmol/min)} = \frac{F}{\text{SA}}
\]

VLDL–TG Clearance (ml/min)

\[
= \frac{\text{VLDL–TG Ra (μmol/min)}}{\text{VLDL–TG concentration (μmol/ml)}}
\]

VLDL–TG fatty acid oxidation – primed-constant infusion:

Fractional oxidation of the infused [1-14C]VLDL–TG was calculated as follows:

\[
\text{Fractional VLDL–TG oxidation} = \frac{14\text{CO}_2 \times \text{SA} \times \text{VCO}_2}{k \times \text{Ar} \times F}
\]

Here, k is the volume of CO2 at 20 °C and 1 atm. pressure (22.4 l/mol), and Ar is the fractional acetate carbon recovery factor in breath CO2, and F is the tracer infusion rate. Sidossis et al. (13) has previously calculated Ar to be 0.56 for resting conditions. The total VLDL–TG oxidation rate (μmol/min) was
calculated as follows:

\[
\text{VLDL–TG oxidation rate} = \text{fractional VLDL–TG oxidation} \times \text{VLDL–TG Ra}
\]

**Statistical analysis**

Results were expressed as mean ± s.d. (parametric data) unless otherwise specified. Statistical comparisons between study days were assessed by paired t-test or Wilcoxon’s test. \( P < 0.05 \) was considered significant.

Sample size was determined as follows: based on our volunteers body composition, presumed VLDL–TG levels, and previous studies done in our lab, we considered average basal VLDL–TG production rates of 50 \( \mu \)mol/min with s.d. 10 \( \mu \)mol/min realistic. Risk of type I and II errors (\( \alpha \) and \( \beta \)) was set at 5% giving us a power of 95%. Earlier studies have indicated that VLDL–TG production rates may be augmented by 32–40% by month-long estrogen administration (14, 15). Therefore, estimated differences between study days to be ~25% or 12.5 \( \mu \)mol/min. Sample size can then be calculated as

\[
n = \frac{(C_2 \alpha + C_\beta)^2 \times \text{s.d.}^2}{\Delta^2},
\]

where \( C_2 \alpha = \text{constant for type I error (two-sided)} \), \( C_\beta = \text{constant for type II error (power 95%)} \), and \( \Delta = \text{estimated difference} \). In our case, this gives

\[
n = (1.96 + 1.645)^2 \times (10)^2 / 12.5^2 = 8 \text{ subjects}.
\]

**Results**

**Circulating hormones and metabolites**

By design, all participants had E\(_2\) concentrations below detection threshold on the placebo study day, while administration of 4 mg E\(_2\) resulted in an increase to premenopausal levels ((placebo versus E\(_2\)) E\(_2\) (nM): 0.07 ± 0.01 vs 0.25 ± 0.04, \( P < 0.001 \)) by the end of the study period. E\(_2\) treatment tended to lower circulating FFA, although not statistically significant (FFA (mM): 0.61 ± 0.13 vs 0.52 ± 0.14, \( P = 0.25 \)). Total TG concentrations were comparable (TG (mM): 1.22 ± 0.59 vs 1.10 ± 0.33, \( P = 0.48 \)).

**Lipid and glucose oxidation**

Lipid oxidation tended to decrease during E\(_2\) treatment (lipid oxidation (mg/kg per min): 0.66 ± 0.32 vs 0.47 ± 0.08, \( P = 0.12 \)); in contrast, glucose oxidation increased significantly (glucose oxidation (mg/kg per min): 1.02 ± 0.20 vs 1.40 ± 0.36, \( P = 0.03 \)).

**VLDL–TG kinetics**

VLDL–TG SA and VLDL–TG concentrations are depicted in Fig. 1A and B. As seen, SA increased tenfold during the primed-continuous infusion, and isotopic steady state was present throughout the sampling period.
VLDL–TG production (VLDL–TG production (µmol/min): 20.0 ± 12.4 vs 24.1 ± 10.7, \( P = 0.33 \)) and clearance rates (VLDL–TG clearance rates (ml/min): 51.4 ± 16.8 vs 64.9 ± 28.8, \( P = 0.34 \)) are presented in Fig. 1C and D. No significant difference in VLDL–TG production or clearance rate was observed.

**VLDL–TG fractional oxidation**

Fractional VLDL–TG oxidation (Fig. 2B) was not affected by E2 treatment (Fractional VLDL–TG oxidation: 0.57 ± 0.17 vs 0.53 ± 0.08, \( P = 0.53 \)). Likewise, absolute VLDL–TG oxidation (VLDL–TG oxidation (µmol/min): 12.3 ± 10.9 vs 12.6 ± 5.6, \( P = 0.93 \)) did not differ significantly between study days.

**Discussion**

Although long-term estrogen treatment is known to increase plasma TG (2), little is known about the immediate effect on hepatic VLDL–TG production and peripheral clearance. The present study is the first to provide data demonstrating that a single dose of E2 (4 mg) does not result in measurable changes in hepatic VLDL–TG production or oxidation in humans.

The high density of ERs on hepatocytes (16) has lead authors to speculate that E2 impacts on hepatic VLDL particle formation and secretion. Indeed, animal studies have shown that E2 stimulates hepatocyte VLDL–TG production and secretion (5, 6). Moreover, a few human tracer studies have demonstrated that long-term E2 treatment augments hepatic VLDL–TG (14) secretion as well as VLDL apoB secretion (i.e. particle number) (17).

However, there are several points favoring the notion that E2 could augment VLDL–TG production acutely: i) estrogens exert their effects not only via nuclear but also through membrane-bound receptors (7) enabling a rapid intracellular signaling response in the hepatocyte to changes in E2 levels. ii) TG levels fluctuate during the day in healthy humans, and are modified within hours through changes in circulating hormones (e.g. insulin and GH) or metabolites (e.g. glucose and FFAs). iii) The increase in E2 levels observed during the end of the follicular phase is in some studies (18) mirrored by a concomitant increase in TG levels. The impact of menstrual phase on VLDL–TG kinetics was therefore further explored by Magkos et al. (19), who, contrary to the author’s initial hypotheses, found no effect of menstrual phase on VLDL–TG kinetics. However, that particular study was not designed to delineate the independent effects of E2 perturbations on VLDL–TG kinetics but rather the combined effects of hormonal changes (E2 and progesterone) during the menstrual cycle. Indeed, Wolfe et al. (20) demonstrated that estrogen combined with micronized progesterone administered for 7 weeks does not result in changes in VLDL particle turnover or VLDL–TG concentrations.

![Figure 2](image-url)
decreased circulating FFAs (as also observed − albeit not significantly − in this study). It therefore seems plausible that E2 treatment alters hepatic VLDL–TG formation via slow genomic effects on enzymes involved in both VLDL–TG synthesis and VLDL particle formation.

Oral estrogen treatment has been demonstrated to decrease lipid oxidation in a dose-dependent manner in humans (22), and has been shown to reduce ketogenesis (a by-product of hepatic lipid oxidation) in cell culture studies (23). E2 action in the liver therefore likely involves channeling FFAs from oxidative to nonoxidative pathways (primarily VLDL–TG production). We therefore hypothesized that peripheral VLDL–TGs would be diverted in a similar manner away from oxidation and toward storage, i.e. that VLDL–TG oxidation in skeletal muscle would decrease following E2 exposure. Again, our finding of no significant change in VLDL–TG oxidation supports the notion that E2 affects lipid metabolism via slow pathways, both in the liver and in peripheral tissues. We chose a dose of 4 mg of E2 in order to make sure that we would achieve premenopausal circulating levels of serum E2 in the pre-menopausal range, which is often not achieved with lower doses (1−2 mg) of E2 often used in the typical postmenopausal setting (24, 25). A limitation to the study is the possible type 2 statistical error due to the low number of subjects. Although our power calculation shows that eight subjects in a cross over design is sufficient to detect a statistical difference, our results need to be confirmed in larger studies. Our results cannot be extended to describe the effects of other routes of delivery, e.g. transdermal estrogen. While oral estrogen results in greater concentrations and VLDL–TG particle production (Apo-B100), transdermal estrogen administration results in unchanged or reduced VLDL–TG concentrations (26) and unchanged VLDL–TG particle production. The latter finding is, to our knowledge, only reported in one study by Walsh et al. (1). Moreover, we cannot conclude whether short-term treatment (e.g. 1 week) is sufficient to elicit statistical differences in VLDL-kinetics or whether treatment withdrawal results in rapid reversal of such effects. Thus, future studies should address the effect of short-term treatment and as well as the impact of treatment withdrawal in order to gain a more complete knowledge of the time-dependent changes in VLDL-kinetics. In summary, short-term E2 exposure does not alter VLDL–TG production, clearance, or oxidation in healthy postmenopausal women. These data therefore indicate that HRT-associated dyslipidemia has a gradual rather than immediate onset.

Declaration of interest
I. C Gormsen, C Host, B E Hjerrild, and S Nielsen have no disclosures. C Gravholt has received lecture fees from Novo Nordisk and Genentech. S Nielsen has received lecture fees from Sanofi-Aventis and MSD.

Funding
The study was supported by grants to C Gravholt from the Danish Medical Research Council (grant number 22-01-0395) and the Novo Nordic Foundation and from grants to S Nielsen from the Danish Medical Research Council (grant number 271-07-0640), the Novo Nordic Foundation, and the Danish Diabetes Foundation.

Acknowledgements
The authors thank Anette Mengel for excellent technical assistance.

References

www.eje-online.org


Received 8 June 2010
Accepted 21 June 2010